Breakthrough T1D Funds SAB Biotherapeutics' Expanded Trial for Late-Stage Type 1 Diabetes
Event summary
- Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 Type 1 Diabetes patients diagnosed between 100 days and 2 years prior.
- The study aims to assess whether SAB-142 can preserve endogenous C-peptide and modulate immune responses beyond the initial 100-day window post-diagnosis.
- SAB Biotherapeutics will co-fund the trial, extending its clinical evaluation of SAB-142 alongside the ongoing Phase 2b SAFEGUARD trial.
The big picture
The PRISE-hATG study represents a strategic shift in focusing on Type 1 Diabetes patients beyond the early diagnosis window, addressing an unmet need in the autoimmune disease space. This trial could validate SAB-142 as a best-in-class therapy if successful, potentially altering the treatment paradigm for millions of patients living with T1D.
What we're watching
- Therapeutic Expansion
- Whether SAB-142 can demonstrate efficacy in patients beyond the initial 100-day window, potentially broadening its market potential.
- Clinical Trial Dynamics
- The pace at which data from the PRISE-hATG study will be available and how it compares to results from the ongoing SAFEGUARD trial.
- Funding and Partnerships
- How Breakthrough T1D's grant and University of Florida's involvement will influence future collaborations and funding for SAB Biotherapeutics' pipeline.
Related topics